MeSH | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (D015452)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma D015452

Diseases [C] » Immune System Diseases [C20] » Immunoproliferative Disorders » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Diseases [C] » Neoplasms [C04] » Neoplasms by Histologic Type » Leukemia » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Diseases [C] » Hemic and Lymphatic Diseases [C15] » Lymphatic Diseases » Lymphoproliferative Disorders » Leukemia, Lymphoid » Precursor Cell Lymphoblastic Leukemia-Lymphoma » Precursor B-Cell Lymphoblastic Leukemia-Lymphoma

Description

A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia. MeSH

Hierarchy View

View MeSH Tree

Approved Indicated Drugs (2)

blinatumomab (blincyto)

inotuzumab ozogamicin (besponsa)

Phase 4 Indicated Drugs (17)

asparaginase (elspar)

bortezomib (velcade)

cyclophosphamide (cytoxan)

cytarabine (cytosar-u)

dasatinib (sprycel)

daunorubicin (cerubidine)

doxorubicin (Doxil)

fludarabine (fludara)

flumatinib

idarubicin (idamycin)

imatinib (gleevec)

mercaptopurine (purinethol)

naltrexone (revia)

prednisone (meticorten)

tioguanine (Lanvis)

urea

vincristine (oncovin)

Phase 3 Indicated Drugs (38)

aldoxorubicin

allogeneic cord blood

allogeneic hematopoietic stem cells (Hemacord)

allogeneic stem cells

Anti-thymocyte Globulin (Rabbit) (Thymoglobulin)

autologous umbilical cord blood

calcium phosphate

clofarabine (clolar)

cyclosporine (sandimmune)

dexamethasone

dexrazoxane (zinecard)

erwinia asparaginase (Erwinaze)

ery001

etoposide (vepesid)

glucarpidase (voraxaze)

humanised anti-cd22 antibody

ifosfamide (ifex)

lestaurtinib

leucovorin

melphalan (alkeran)

mesna (mesnex)

methotrexate

methylprednisolone (medrol)

mitoxantrone (novantrone)

muromonab cd3 (Orthoclone OKT3)

mycophenolate (myfortic)

nelarabine (arranon)

nicord

pegaspargase (oncaspar)

peripheral blood hematopoietic cell

ponatinib (iclusig)

prednisolone (hydeltra)

sargramostim (leukine)

sirolimus (rapamune)

tacrolimus (prograf)

thiotepa

tisagenlecleucel (Kymriah)

vindesine

Phase 2 Indicated Drugs (104)

90y-dota-epratuzumab

aciclovir (zovirax)

adct-602

aldesleukin (proleukin)

alemtuzumab (campath)

allogeneic bone marrow

allogeneic cd19 car-t cells

allogeneic cytomegalovirus-specific cytotoxic t lymphocytes

allogeneic lymphocytes

allopurinol (zyloprim)

alt-803

alvocidib

anti-cd19/20-car vector-transduced t cells

atorvastatin (lipitor)

autologous anti-cd19car-4-1bb-cd3zeta-egfrt-expressing t lymphocytes

autologous cd19/cd22 chimeric antigen receptor t-cells

autologous hematopoietic cell

autologous regulatory t cells

azacitidine (vidaza)

beclomethasone (vanceril)

bendamustine (treanda)

beractant (survanta)

bind19

bkt-140

bosutinib (bosulif)

busulfan (myleran)

carboplatin (paraplatin)

carcik-cd19

CAR-ITNK

cd19car-cd3zeta-4-1bb-expressing allogeneic t-lymphocyte cells

cd45-depleted allogenic peripheral blood stem cell

cord blood hematopoietic stem cell

ctl019 transduced cells

curcumin

ds-1594b

entinostat

etanercept (enbrel)

everolimus (zortress)

filgrastim (neupogen)

hemopoietic stem cell

hla-matched related donor bone marrow

hydrocortisone (solu-cortef)

ibrutinib (imbruvica)

idasanutlin

idelalisib (zydelig)

imiquimod (aldara)

interferon alfa-1b

in vitro-treated peripheral blood stem cell

kte-c19

lenalidomide (revlimid)

moxetumomab pasudotox

msk-2206

multi-peptide cmv-modified vaccinia ankara vaccine

nilotinib (tasigna)

nivolumab (opdivo)

nk cell

obi-3424

obinutuzumab (gazyva)

ofatumumab (arzerra)

onc201

ondansetron (zofran)

panobinostat (farydak)

pembrolizumab (keytruda)

plerixafor (mozobil)

pol6326

posaconazole (noxafil)

rasburicase (elitek)

rituximab (rituxan)

romidepsin (istodax)

ruxolitinib (jakafi)

sapanisertib

selumetinib

sorafenib (nexavar)

stem cells

sulfamethoxazole (gantanol)

sunitinib (sutent)

tagraxofusp-erzs (elzonris)

tardamide

t cell depleted hematopoietic stem cells

temsirolimus (torisel)

teniposide (vumon)

t lymphocytes

tocilizumab (actemra)

topotecan (hycamtin)

tresulfan

trimethoprim

veliparib

venetoclax (venclexta)

vinblastine (velban)

voriconazole (vfend)

y90 anti-cd45 monoclonal antibody bc8

Phase 1 Indicated Drugs (89)

4scar19

7-hydroxystaurosporine

abiraterone (zytiga)

acetaminophen (tylenol)

afatinib (gilotrif)

alisertib

apolizumab

asciminib

autologous cd34+ cells

autologous humanized anti-cd19 and anti-cd20 dual specific car-t cells

baffr-car t cells

bc8

bcma/cd19 dual-target car-t

becatecarin

belinostat (beleodaq)

bevacizumab (avastin)

bms-214662

bone marrow cells

bpx-501

cabazitaxel (jevtana kit)

cabozantinib (cometriq)

carfilzomib (kyprolis)

cart22

c-car011

cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t-lymphocytes

cd19 car-nk cells

cd19-cd34 car transduced t cells

cd79b car-t cells

cd8+ and cd4+ donor memory t-cells-expressing ha1-specific tcr

celecoxib (celebrex)

cord blood stem cells

cpi-613

deglycosylated ricin a chain-conjugated anti-cd19/anti-cd22 immunotoxins

depatuxizumab mafodotin

diphenhydramine (benadryl)

enzalutamide (xtandi)

ephb4-hsa fusion protein

erlotinib (tarceva)

et190l1 artemis™ t cells

etc-1907206

fluorouracil (efudex)

ft1050-treated cord blood

in111 anti-cd45 monoclonal antibody bc8

ina03

inactivated influenza vaccine

ipilimumab (yervoy)

ispinesib

ixazomib (ninlaro)

lenvatinib (lenvima)

lp-108

navitoclax

olaparib (lynparza)

oxaliplatin (eloxatin)

palbociclib (ibrance)

pbltt52car19

pegcrisantaspase

perifosine

pertuzumab (perjeta)

pevonedistat

pz01 car-t cells

ranitidine (zantac)

ribociclib (kisqali)

rimiducid

ro4929097

ror1 car-specific autologous t-lymphocytes

rpm cd19-mbil15-car-t cells

temozolomide (temodar)

tetanus-cmv fusion peptide vaccine

thiscart7 cells

trametinib (mekinist)

tretinoin (Retin-A)

triapine

valproic acid (depakene)

vemurafenib (zelboraf)

Other Experimental Indicated Drugs (12)

autologous-allogeneic tandem hematopoietic stem cell

calaspargase pegol

carmustine (bicnu)

cd7 car-t cell

deferasirox (exjade)

foscarnet (foscavir)

ganciclovir (cytovene)

interferon alpha-2b (Intron-A)

lithium (lithonate)

palifermin (kepivance)

rd13-01

valganciclovir (valcyte)

Organization Involved with Phase 2 Indications (10)

Blood and Marrow Transplant Clinical Trials Network

Celgene

Federal University of Rio de Janeiro

Institut de Cancérologie de la Loire (ICLN)

Medical College of Wisconsin

National Cancer Institute (NCI)

National Heart, Lung, and Blood Institute (NHLBI)

National Marrow Donor Program

Rio de Janeiro Federal University

University of Southern California

Organization Involved with Phase 1 Indications (1)

Seattle Genetics

Hierarchy Tree View

MeSH

UMLS Data

YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.